Nrx Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nrx Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Nrx Pharmaceuticals Inc recorded a cumulative net loss of $-22 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -119.48%.

However, within the Healthcare sector 771 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4501, from total ROA ranking in the first quarter of 2026 at 5264.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	630.65 %	56.82 %	254.86 %	236.08 %	-8.09 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-22	-24	-29	-39	-35
Return On Assets (TTM)	-119.48 %	-210.54 %	-283.53 %	-503 %	-677.86 %
NRXP's Total Ranking	# 4501	# 5264	# 4735	# 4837	# 4888
Total Assets (TTM) in million	35	12	13	15	5
Seq. Total Assets Change	196.98 %	-8.13 %	-13.6 %	209.96 %	-36.26 %
Seq. Net Income Change	-	-	-	-	-

NRXP's 5 Years Annual ROA >> Back to NRXP Management Effectiveness >> Compare NRXP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 357
Sector	# 772
Overall	# 4292

Return On Assets Statistics
High	Average	Low
-0.6 %	-421.24 %	-1457.66 %
(Dec 31 2019)		(Mar 31 2021)

Financial Statements
Nrx Pharmaceuticals Inc 's Assets	$ 35 million	NRXP's Balance sheet
Nrx Pharmaceuticals Inc 's Income	$ -17 million	Quarterly NRXP's Income Statement
NRXP's Income by Division		See NRXP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	265.74 %	-50.09 %	-71.66 %	-21.12 %	940.97 %
Total Assets in million	13	4	7	26	33
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-29	-25	-30	-40	-349
Annual Return On Assets	-214.35 %	-688.2 %	-412.17 %	-153.99 %	-1065.98 %

NRXP's 5 Years Annual ROA >> Back to NRXP Management Effectiveness >> Compare NRXP ROA to its Competitors

More Return On Assets Ratios
NRXP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NRXP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NRXP's Competitors
Subscribers only: Roa for Nrx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for NRXP's Customers

You may also want to know
NRXP's Roi	NRXP's Inventory Turnover Ratio	NRXP's Growth Rates	NRXP's Dividend Comparisons
	NRXP's Profitability Ratios	NRXP's Asset Turnover Ratio	NRXP's Dividend Growth
NRXP's Roe	NRXP's Valuation Ratios	NRXP's Financial Strength Ratios	NRXP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-31T08:36:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.